Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 2
1973 2
1974 2
1975 1
1976 1
1977 3
1978 1
1979 5
1980 3
1981 2
1982 2
1984 1
1988 1
1989 3
1990 2
1991 2
1993 3
1994 3
1995 2
1996 3
1997 1
1998 3
1999 2
2000 2
2001 4
2002 1
2003 2
2004 1
2008 1
2010 2
2011 1
2012 1
2014 3
2015 1
2016 6
2017 4
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Results by year

Filters applied: . Clear all
Page 1
Fungal Skin Infections.
Gupta AK, MacLeod MA, Foley KA, Gupta G, Friedlander SF. Gupta AK, et al. Among authors: macleod ma. Pediatr Rev. 2017 Jan;38(1):8-22. doi: 10.1542/pir.2015-0140. Pediatr Rev. 2017. PMID: 28044030 Review. No abstract available.
Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
Gray R, Patel S, Ives N, Rick C, Woolley R, Muzerengi S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE; PD MED Collaborative Group. Gray R, et al. JAMA Neurol. 2022 Feb 1;79(2):131-140. doi: 10.1001/jamaneurol.2021.4736. JAMA Neurol. 2022. PMID: 34962574 Free PMC article. Clinical Trial.
Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.
PD Med Collaborative Group; Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE. PD Med Collaborative Group, et al. Lancet. 2014 Sep 27;384(9949):1196-205. doi: 10.1016/S0140-6736(14)60683-8. Epub 2014 Jun 11. Lancet. 2014. PMID: 24928805 Clinical Trial.
OPDIVO (Nivolumab).
Gupta AK, Macleod MA, Abramovits W. Gupta AK, et al. Among authors: macleod ma. Skinmed. 2015 Dec 1;13(6):471-4. eCollection 2015. Skinmed. 2015. PMID: 26861525 No abstract available.
Enhancing "idling" neurons.
Macleod MA, Francis TJ, Smith DJ. Macleod MA, et al. Lancet. 1990 Apr 7;335(8693):860-1. doi: 10.1016/0140-6736(90)90979-f. Lancet. 1990. PMID: 1969588 No abstract available.
VALCHLOR (Mechlorethamine) 0.02% Gel.
Gupta AK, MacLeod MA, Abramovits W. Gupta AK, et al. Among authors: macleod ma. Skinmed. 2016 Apr 1;14(2):120-2. eCollection 2016. Skinmed. 2016. PMID: 27319956 No abstract available.
Radiation doses.
MacLeod MA. MacLeod MA. Nucl Med Commun. 1994 Jun;15(6):492-3. doi: 10.1097/00006231-199406000-00016. Nucl Med Commun. 1994. PMID: 8078648 No abstract available.
81 results